Cytotoxic effects of violacein in human uveal melanoma cell lines

Melanoma Research

Volumn 14, Issue 5, 2004, Pages 421-424

  Saraiva, Vinicius S ^a,b   Marshall, Jean Claude ^a   Cools Lartigue, Jonathan ^a   Burnier Jr , Miguel N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Henry C Witelson Ocular Pathology Laboratory   (Canada)

Author keywords

Chromobacterium; Experimental therapy; Inhibitory concentration 50; Melanoma; Pharmacology; Uveal neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; RHODAMINE; UNCLASSIFIED DRUG; VIOLACEIN;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER GROWTH; CANCER INHIBITION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PILOT STUDY; PRIORITY JOURNAL; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MELANOMA; MODELS, CHEMICAL; NEOPLASM METASTASIS; PIGMENTS, BIOLOGICAL; TIME FACTORS; UVEAL NEOPLASMS;

EID: 7244260722     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200410000-00014     Document Type: Article

References (21)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32:239-251.
2. McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 1993; 422:433-437.
3. Shields JA. Management of posterior uveal melanoma: past, present, future. Retina 2002; 22:139-142.
4. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-965.
5. Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De Potter P, et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201-208.
6. Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998; 34 (Suppl. 3):S27-S30.
7. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581.
8. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87:840-845.
9. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002; 95:2366-2372.
10. Durán N, Menck CF. Chromobacterium violaceum: a review of pharmacological and industrial perspectives. Crit Rev Microbiol 2001; 27:201-222.
11. Riveros R, Haun M, Durán N. Effect of growth conditions on production of violacein by Chromobacterium violaceum (BB-78 strain). Braz J Med Biol Res 1989; 22:569-577.
12. Leon LL, Miranda CC, De Souza AO, Durán N. Antileishmanial activity of the violacein extracted from Chromobacterium violaceum. J Antimicrob Chemother 2001; 48:449-450.
13. Melo PS, Maria SS, Vidal BC, Haun M, Durán N. Violacein cytotoxicity and induction of apoptosis in V79 cells. In Vitro Cell Dev Biol Anim 2000; 36:539-543.
14. Rettori D, Durán N. Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World J Microbiol Biotechnol 1998; 14:685-688.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
16. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82:1113-1118.
17. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83:757-766.
18. Melo PS, Justo GZ, de Azevedo MB, Durán N, Haun M. Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology 2003; 186:217-225.
19. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Durȧn N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. Blood 2004; 104:1459-1464.
20. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 1997; 8:756-762.
21. Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001; 11:601-609.